newsfilter
← Earnings
Earnings Releases·

Ocugen — Third Quarter 2026 Earnings Summary

Ocugen, Inc. reported third-quarter 2026 financial results showing total operating expenses of $19.7 million and a net loss of $0.01 per share. The company holds $84.6 million in cash and short-term investments, providing a runway into 2028. Clinically, Ocugen received provisional approval and priority designation for OCU400 in The Bahamas, initiated dosing in the Phase 3 ArMaDa3 trial for OCU410, and executed an exclusive license agreement for OCU400 in the Middle East and North Africa with Roots Pharmaceutical.

Company
OCUGEN INC
Sector
Healthcare
Industry
Biotechnology